Drug Profile
Rifampicin - GeneCare Research
Alternative Names: GK-001Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator GeneCare Research Institute
- Class Antibacterials; Antineoplastics; Antituberculars; Hepatoprotectants; Rifamycins
- Mechanism of Action Angiogenesis inhibitors; Oxidoreductase inhibitors; Transaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 28 Sep 2021 No development reported - Phase-III for Liver cancer (Prevention) in Japan (PO)
- 31 Mar 2017 GeneCare Research Institute completes two phase-III trials in liver cancer (prevention of recurrence in patients with chronic hepatitis) in Japan (UMIN000007667; UMIN000007668)
- 15 Mar 2016 Rifampicin is still in phase III trials for liver cancer (Prevention of recurrence in patients with chronic hepatitis) in Japan (PO)